logo-loader
LON:MTFB

Motif Bio PLC

Receive alerts
Market:
LON
Market Cap:
£9.08 m
Price
£0.03
Change
-3.64%
52 weeks high
44.90
52 weeks low
2.00

Viewing results 1-25 of 168

Health

Motif Bio prepares for new iclaprim study

Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections ...

3 days, 8 hours ago
Health

Motif Bio assessing lead drug iclaprim potential as a combatant for the life-threatening infection listeria

Partner JMI Laboratories will use pre-clinical services provided by National Institute of Allergy and Infectious Diseases, to assess the antibiotic...

6 days, 15 hours ago
Tech

Amphion Innovations keen to hold onto Polarean Imaging stake

Amphion Innovations provides “concentrated but well-managed portfolio” in high growth sectors...

1 week, 5 days ago
Tech

Amphion Innovations keen to hold onto Polarean Imaging stake

Amphion Innovations provides “concentrated but well-managed portfolio” in high growth sectors...

1 week, 5 days ago
Health

Motif Bio's lender postpone's loan amortisation date by one month

Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy....

3 weeks, 3 days ago
Health

Motif Bio to meet US regulator on September 19 to discuss trial design

The Food & Drug Administration in an earlier discussion urged Motif to carry out a further trial to allay concerns over liver toxicity...

4 weeks, 2 days ago
Health

Motif Bio PLC requests meeting with US regulator to discuss trial design

It has made the request after being encouraged by the US Food & Drug Administration to carry out further work on flagship drug iclaprim ...

on 15/7/19
Tech

Amphion Innovations delays publication of 2018 accounts

“The reason for the delay is continuing work with the company's auditors in relation to the going concern status of the company”...

on 27/6/19
Health

Motif Bio presents new iclaprim data at industry conference in California

Motif presented three new posters, tackling iclaprim’s dosage, the diversity of patients who have taken part in clinical trials, and the antibiotic’s ability to fight off drug-resistant bacteria...

on 24/6/19
Health

Motif Bio says US drugs regulator has encouraged it to carry out further study on antibiotic

The guidance was contained in minutes from a meeting with the Food & Drug Administration in early May ...

on 6/6/19
Health

Motif Bio boss “very confident” in potential of flagship antibiotic

Motif Bio is working with US regulators as it tries to get approval for iclaprim, while the antibiotic has also shown potential as a treatment for certain lung and eye infections...

on 22/5/19
Health

Motif Bio teams up with German university to see if iclaprim can help patients with rare eye disease

Researchers at the Otto-von-Guericke University Magdeburg are to carry out a series of lab tests to evaluate iclaprim as a possible treatment for toxoplasma chorioretinitis...

on 22/5/19
Health

Motif Bio to present three iclaprim posters at industry conference in San Francisco next month

The three posters will contain data on Motif Bio’s lead product, a next-generation antibiotic...

on 21/5/19
Health

Motif Bio meets FDA

The company expects to be furnished with minutes from its meeting in the next 30 days, allowing it to chart a path for its lead drug...

on 7/5/19
Health

Motif Bio partners up with Scottish biotech to develop iclaprim as cystic fibrosis lung infection treatment

Based on early data, Motif Bio thinks iclaprim antibiotic would work well alongside Lamellar Biomedical’s LMS-611, and so an in vivo study will now be carried out...

on 1/5/19
Health

Motif Bio higher as it presents data from Phase III iclaprim trial

The presentation provided a drill-down in the results from the company’s REVIVE study...

on 16/4/19
Health

Motif Bio still hopeful of reaping the benefit from a productive year

Securing approval in the US for iclaprim remains the top priority for Motif Bio, the company said as it posted full-year 2018 results which saw losses narrow sharply...

on 15/4/19
Health

Motif Bio receives vote of confidence as it raises £2.7mln

Chief executive Graham Lumsden said: "We are encouraged by the support shown by both new and existing investors as we strengthen our balance sheet"...

on 26/3/19
Health

Circassia enters pivotal week with two big FDA decisions due

By Sunday, Circassia will know whether its Duaklir COPD inhaler has been approved for sale in the US and whether Tudorza's supplemental NDA has been given the thumbs-up...

on 25/3/19
Health

Motif Bio PLC says it is in the advanced stages of concluding a proposed placing to institutional and other investors

It said the net proceeds of the proposed placing, when taken together with its existing cash resources are expected to be sufficient to fund the business beyond its meeting with the US FDA...

on 25/3/19
Health

Motif Bio surges as US FDA agrees to a meeting to discuss new drug application for novel antibiotic iclaprim

The AIM-listed firm said the meeting with the US watchdog is scheduled to take place on May 3, 2019, with official meeting minutes typically received from the FDA within 30 days of a meeting...

on 20/3/19
Tech

Amphion Innovations sells further batch of shares in partner Motif Bio, raising proceeds of US$240,656

The AIM-listed firm said it sold 3,250,000 Motif Bio shares, reducing its holding in the company to 20,179,611 ordinary shares, representing 6.78% of the issued share capital...

on 19/3/19